 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug HALOPERIDOL: Haloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in [0m
[34mpredisposed patients or those receiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not [0m
[34mspecifically mention myocardial infarction in this context.[0m
[1;34m2[0m[34m. Drug THIOTHIXENE: DO-NOT-KNOW[0m

[34mThe FDAHandler has indicated that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. While the label mentions cardiovascular effects such as [0m
[34mtachycardia, hypotension, lightheadedness, and syncope, and nonspecific EKG changes in some patients, the clinical significance of these changes is not known. Additionally, there is an increased risk [0m
[34mof death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for this use. Given the [0m
[34mlack of specific information regarding myocardial infarction, we cannot definitively say whether thiothixene increases or decreases the risk of this condition.[0m
[1;34m3[0m[34m. Drug PIMOZIDE: The FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT [0m
[34minterval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart [0m
[34mhealth, the direct effect on myocardial infarction risk is not explicitly stated in the FDA label.[0m
[34m                ---------[0m
[34m                Does the typical antipsychotic category of drugs increase the risk of[0m
[34m                myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug HALOPERIDOL: Haloperidol is associated with cardiovascular effects that could suggest an increased risk of serious cardiac events such as myocardial infarction, especially in [0m
[34mpredisposed patients or those receiving high doses. However, there is no conclusive evidence directly linking haloperidol to an increased risk of myocardial infarction, as the FDA label does not [0m
[34mspecifically mention myocardial infarction in this context.[0m
[1;34m2[0m[34m. Drug THIOTHIXENE: DO-NOT-KNOW[0m

[34mThe FDAHandler has indicated that thiothixene has not been specifically reported to increase or decrease the risk of myocardial infarction. While the label mentions cardiovascular effects such as [0m
[34mtachycardia, hypotension, lightheadedness, and syncope, and nonspecific EKG changes in some patients, the clinical significance of these changes is not known. Additionally, there is an increased risk [0m
[34mof death from cardiovascular causes in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, although it is not approved for this use. Given the [0m
[34mlack of specific information regarding myocardial infarction, we cannot definitively say whether thiothixene increases or decreases the risk of this condition.[0m
[1;34m3[0m[34m. Drug PIMOZIDE: The FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT [0m
[34minterval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart [0m
[34mhealth, the direct effect on myocardial infarction risk is not explicitly stated in the FDA label.[0m
[34m                ---------[0m
[34m                Does the typical antipsychotic category of drugs increase the risk of[0m
[34m                myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe reasoning provided by the user is based on the information from the FDA labels for three typical [0m
[32mantipsychotic drugs: haloperidol, thiothixene, and pimozide. The user correctly notes that while there are cardiovascular effects associated with these drugs, there is no conclusive evidence directly [0m
[32mlinking them to an increased risk of myocardial infarction. The user also correctly identifies that the FDA label for thiothixene does not specifically report an increase or decrease in the risk of [0m
[32mmyocardial infarction, and that while pimozide can prolong the QT interval, which is a risk factor for ventricular arrhythmia, there is no explicit statement about the direct effect on myocardial [0m
[32minfarction risk.[0m

[32mGiven that the FDA labels for these drugs do not provide conclusive evidence of an increased risk of myocardial infarction, and that the user has not presented any other evidence to suggest otherwise,[0m
[32mthe reasoning appears to be consistent with the information provided. The user has appropriately concluded that there is no clear effect on the risk of myocardial infarction from the typical [0m
[32mantipsychotic category of drugs based on the available FDA label information for these drugs.[0m

[32mTherefore, based on the passages provided and the reasoning process, there does not seem to be a flaw in the user's reasoning. The conclusion that there is no clear effect on the risk of myocardial [0m
[32minfarction from the typical antipsychotic category of drugs is consistent with the evidence presented.[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            You MUST use the `feedback` tool/function in your next[0m
[31m            message.  If possible, send the critique you intended for[0m
[31m            the user's provided reasoning. If that is not possible or[0m
[31m            if you would simply acknowledge this message, you must[0m
[31m            instead use the `feedback` tool with `critique` set to [0m[31m""[0m[31m.[0m
[31m            [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mYour reasoning is valid, no feedback was provided.[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m
 [1m([0mCritic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            You MUST use the `feedback` tool/function in your next[0m
[31m            message.  If possible, send the critique you intended for[0m
[31m            the user's provided reasoning. If that is not possible or[0m
[31m            if you would simply acknowledge this message, you must[0m
[31m            instead use the `feedback` tool with `critique` set to [0m[31m""[0m[31m.[0m
[31m            [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the typical antipsychotic category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 [0m[32m([0m[32mHaloperidol[0m[32m)[0m[32m: Indicates a potential association with cardiovascular effects and a possible increased risk of serious cardiac events, but lacks conclusive evidence directly linking it[0m
[32mto myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 2 [0m[32m([0m[32mThiothixene[0m[32m)[0m[32m: Does not provide specific information on myocardial infarction risk, but mentions cardiovascular effects and an increased risk of death from cardiovascular causes in a [0m
[32mspecific population [0m[32m([0m[32melderly patients with dementia-related psychosis[0m[32m)[0m[32m."[0m[32m,[0m
[32m      [0m[32m"Passage 3 [0m[32m([0m[32mPimozide[0m[32m)[0m[32m: Mentions a potential risk factor [0m[32m([0m[32mQT interval prolongation[0m[32m)[0m[32m related to heart health, but does not explicitly state an effect on myocardial infarction risk."[0m[32m,[0m
[32m      [0m[32m"Overall, the passages suggest that there may be cardiovascular risks associated with typical antipsychotics, but there is no clear, direct evidence linking these drugs as a category to an [0m
[32mincreased risk of myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect on the risk of myocardial infarction from the typical antipsychotic category of drugs."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the typical antipsychotic category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 [0m[34m([0m[34mHaloperidol[0m[34m)[0m[34m: Indicates a potential association with cardiovascular effects and a possible increased risk of serious cardiac events, but lacks conclusive evidence directly linking it[0m
[34mto myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 2 [0m[34m([0m[34mThiothixene[0m[34m)[0m[34m: Does not provide specific information on myocardial infarction risk, but mentions cardiovascular effects and an increased risk of death from cardiovascular causes in a [0m
[34mspecific population [0m[34m([0m[34melderly patients with dementia-related psychosis[0m[34m)[0m[34m."[0m[34m,[0m
[34m      [0m[34m"Passage 3 [0m[34m([0m[34mPimozide[0m[34m)[0m[34m: Mentions a potential risk factor [0m[34m([0m[34mQT interval prolongation[0m[34m)[0m[34m related to heart health, but does not explicitly state an effect on myocardial infarction risk."[0m[34m,[0m
[34m      [0m[34m"Overall, the passages suggest that there may be cardiovascular risks associated with typical antipsychotics, but there is no clear, direct evidence linking these drugs as a category to an [0m
[34mincreased risk of myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect on the risk of myocardial infarction from the typical antipsychotic category of drugs."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the typical antipsychotic category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m [0m[1;31m([0m[31mHaloperidol[0m[1;31m)[0m[31m: Indicates a potential association with cardiovascular effects and a possible increased risk of serious cardiac events, but lacks conclusive evidence directly [0m
[31mlinking it to myocardial infarction.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m [0m[1;31m([0m[31mThiothixene[0m[1;31m)[0m[31m: Does not provide specific information on myocardial infarction risk, but mentions cardiovascular effects and an increased risk of death from cardiovascular causes in a [0m
[31mspecific population [0m[1;31m([0m[31melderly patients with dementia-related psychosis[0m[1;31m)[0m[31m.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m [0m[1;31m([0m[31mPimozide[0m[1;31m)[0m[31m: Mentions a potential risk factor [0m[1;31m([0m[31mQT interval prolongation[0m[1;31m)[0m[31m related to heart health, but does not explicitly state an effect on myocardial infarction risk.[0m
[1;31m4[0m[31m. Overall, the passages suggest that there may be cardiovascular risks associated with typical antipsychotics, but there is no clear, direct evidence linking these drugs as a category to an increased[0m
[31mrisk of myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect on the risk of myocardial infarction from the typical antipsychotic category of drugs.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.7[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.0[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The passages suggest potential cardiovascular risks associated with typical antipsychotics, but there is no conclusive evidence directly linking these drugs as a category to an [0m
[32mincreased risk of myocardial infarction. The evidence is considered weak because it is based on the absence of specific information and the lack of direct association in the FDA labels for the drugs [0m
[32mmentioned."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
